Research programme: stem cell therapy - ID Pharma/ Sangamo Therapeutics
Latest Information Update: 12 Jan 2017
At a glance
- Originator ID Pharma
- Developer ID Pharma; Sangamo BioSciences; Wellcome Trust Sanger Institute
- Class Gene therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency
Most Recent Events
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
- 05 Jan 2016 Discontinued for Alpha 1-antitrypsin deficiency in Japan (Parenteral)
- 13 Oct 2011 Early research in Alpha 1-antitrypsin deficiency in Japan (Parenteral)